NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,183,627 | +34.5% | 3,666,264 | +29.9% | 0.01% | +66.7% |
| Q2 2023 | $1,622,996 | -5.0% | 2,821,620 | +3.1% | 0.00% | -25.0% |
| Q1 2023 | $1,708,530 | +77.8% | 2,738,029 | +518.3% | 0.00% | +100.0% |
| Q4 2022 | $961,002 | +36.5% | 442,858 | +100.5% | 0.00% | 0.0% |
| Q3 2022 | $704,000 | -62.9% | 220,840 | -55.8% | 0.00% | -50.0% |
| Q2 2022 | $1,896,000 | +93.1% | 499,592 | +174.3% | 0.00% | +100.0% |
| Q1 2022 | $982,000 | -96.2% | 182,157 | -75.9% | 0.00% | -93.1% |
| Q2 2019 | $25,968,000 | -36.6% | 755,535 | -38.6% | 0.03% | -32.6% |
| Q1 2019 | $40,987,000 | +15.2% | 1,230,092 | +13.6% | 0.04% | +4.9% |
| Q4 2018 | $35,584,000 | +66.3% | 1,082,569 | +208.5% | 0.04% | +105.0% |
| Q3 2018 | $21,395,000 | +213.3% | 350,969 | +151.0% | 0.02% | +185.7% |
| Q2 2018 | $6,828,000 | -72.0% | 139,837 | -39.0% | 0.01% | -73.1% |
| Q1 2018 | $24,363,000 | +135.5% | 229,273 | +32.3% | 0.03% | +136.4% |
| Q4 2017 | $10,346,000 | +3804.2% | 173,239 | +1179.6% | 0.01% | – |
| Q2 2017 | $265,000 | +12.3% | 13,538 | +34.6% | 0.00% | – |
| Q1 2017 | $236,000 | -42.7% | 10,058 | -70.0% | 0.00% | -100.0% |
| Q4 2016 | $412,000 | -51.9% | 33,553 | -32.7% | 0.00% | 0.0% |
| Q3 2016 | $856,000 | +82.5% | 49,837 | +51.1% | 0.00% | 0.0% |
| Q2 2016 | $469,000 | +44.8% | 32,974 | +40.0% | 0.00% | 0.0% |
| Q1 2016 | $324,000 | +88.4% | 23,558 | +71.6% | 0.00% | – |
| Q2 2015 | $172,000 | -87.5% | 13,731 | -89.0% | 0.00% | -100.0% |
| Q1 2015 | $1,374,000 | -18.5% | 124,861 | +14.8% | 0.00% | -25.0% |
| Q4 2014 | $1,686,000 | +58.3% | 108,761 | +23.3% | 0.00% | +33.3% |
| Q3 2014 | $1,065,000 | -55.2% | 88,200 | -52.4% | 0.00% | -50.0% |
| Q2 2014 | $2,377,000 | -26.1% | 185,400 | -30.1% | 0.01% | -40.0% |
| Q1 2014 | $3,217,000 | +79.0% | 265,400 | +67.7% | 0.01% | +100.0% |
| Q4 2013 | $1,797,000 | +124.6% | 158,300 | +106.8% | 0.01% | +66.7% |
| Q3 2013 | $800,000 | +2.3% | 76,548 | +13.0% | 0.00% | 0.0% |
| Q2 2013 | $782,000 | -7.0% | 67,748 | -40.3% | 0.00% | -25.0% |
| Q4 2012 | $841,000 | – | 113,448 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rhenman & Partners Asset Management AB | 508,000 | $6,132,000 | 1.80% |
| Bodri Capital Management, LLC | 250,000 | $3,018,000 | 1.46% |
| Granahan Investment Management | 3,442,980 | $41,557,000 | 1.28% |
| TIRSCHWELL & LOEWY INC | 603,441 | $7,284,000 | 1.22% |
| NEA Management Company, LLC | 1,825,600 | $22,035,000 | 1.12% |
| Cormorant Asset Management, LP | 450,000 | $5,432,000 | 1.12% |
| HARVEY CAPITAL MANAGEMENT INC | 221,750 | $2,676,000 | 1.05% |
| Cheyne Capital Management (UK) LLP | 229,577 | $2,772,000 | 0.99% |
| Artal Group S.A. | 1,650,000 | $19,916,000 | 0.73% |
| FIC CAPITAL INC | 147,293 | $1,778,000 | 0.71% |